https://www.europeanpharmaceuticalreview.com/eli-lilly-bolsters-infectious-disease-portfolio-with-acquisitions-totalling-38bn/2135567.article European Pharmaceutical Review en 2026-05-27T11:39:00+01:00 Eli Lilly bolsters infectious disease portfolio with acquisitions totalling $3.8bn vaccines,Eli Lilly and Company https://www.europeanpharmaceuticalreview.com/pharming-secures-novel-eu-approval-for-joenja-in-activated-pi3k-delta-syndrome/2135541.article European Pharmaceutical Review en 2026-05-26T10:56:00+01:00 Pharming secures novel EU approval for Joenja in activated PI3K delta syndrome European Commission (EC),Rare diseases,Regulation and compliance